22 August 2012
EMA/PDCO/530890/2012
Paediatric Committee (PDCO)

PDCO monthly report of opinions on paediatric investigation plans and other activities

15-17 August 2012

Opinions on paediatric investigation plans

The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines:

- Pegylated B-domain-deleted sequence-modified recombinant human factor VIII, from Bayer Pharma AG, in the therapeutic area of haematology-hemostaseology;
- Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Victoria lineage) / Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Yamagata lineage) / Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain / Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, from Sanofi Pasteur SA, Sanofi Pasteur MSD, in the therapeutic area of haematology-haemostaseology;
- Ioforminol, from GE Healthcare, in the therapeutic area of diagnostic medicines;
- Recombinant single chain coagulation factor VIII, from CSL Behring GmbH, in the therapeutic area of haematology-haemostaseology
- Glycopegylated Recombinant Coagulation Factor VIII, from Novo Nordisk A/S, in the therapeutic area of haematology-haemostaseology;

A PIP sets out a programme for the development of a medicine in the paediatric population. The PIP aims to generate the necessary quality, safety and efficacy data through studies to support the authorisation of the medicine for use in children of all ages. These data have to be submitted to the European Medicines Agency, or national competent authorities, as part of an application for a marketing authorisation for a new medicine, or for one covered by a patent. In some cases, a PIP may include a waiver of the studies in one or more paediatric subsets, or a deferral.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 77523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinions on product-specific waivers

The PDCO adopted positive opinions for product-specific waivers, recommending that the obligation to submit data obtained through clinical studies with children be waived in all subsets of the paediatric population, for the following medicines:

- Acetylsalicylic acid / rosuvastatin, from EGIS Pharmaceuticals PLC, in the therapeutic area of cardiovascular diseases;
- Chlortalidone / azilsartan medoxomil, from Takeda Global Research and Development Centre (Europe) Limited, in the therapeutic area of cardiovascular diseases;
- Icosapent Ethyl, from Amarin Pharmaceuticals Ireland Limited, in the therapeutic area of cardiovascular diseases;
- Lapatinib ditosylate monohydrate, from Glaxo Group Ltd, in the therapeutic area of oncology;

Waivers can be issued if there is evidence that the medicine concerned is likely to be ineffective or unsafe in the paediatric population, or that the disease or condition targeted occurs only in adult populations, or that the medicine, or the performance of trials, does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Opinions on modifications to an agreed PIP

The PDCO also adopts, every month, opinions on modifications to an agreed PIP, which can be requested by the applicant when the plan is no longer appropriate or when there are difficulties that render the plan unworkable. The PDCO adopted positive opinions, agreeing change(s), for the following products:

- Influenza virus surface antigens (haemagglutinin (HA) and neuraminidase) A/California/7/2009 (H1N1) – like strain used A/Brisbane/10/2010 A/Perth/16/2009 (H3N2) - like strain used NYMC X-187 derived from A/Victoria/210/2009 B/Brisbane/60/2008, from Novartis Vaccines and Diagnostics BV, in the therapeutic area of vaccines;
- Dasatinib (monohydrate), from Bristol-Myers Squibb Pharma EEIG, in the therapeutic area of oncology;
- Ataluren (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid), from PTC Therapeutics Limited, in the therapeutic area of neurology;
- Retigabine, from Glaxo Group Limited, in the therapeutic area of neurology;
- Ceftobiprole medocaril sodium, from Basilea Pharmaceutica International Ltd., in the therapeutic area of infectious diseases;
- Chloroprocaine Hydrochloride, from Sintetica Italia S.r.l., in the therapeutic area of anaesthesiology;
- Pitavastatin, from Kowa Pharmaceutical Europe Company Ltd, in the therapeutic area of endocrinology-gynaecology-fertility-metabolism;
- Human Cell Line recombinant human Factor VIII (human-cl rhFVIII) / Human Coagulation Factor VIII (rDNA), from Octapharma Pharmazeutika Produktionsges.m.b.H, in the therapeutic area of haematology-hemostaseology;
- Ustekinumab, from Janssen-Cilag International NV, in the therapeutic area of immunology-rheumatology-transplantation / dermatology;

- Denosumab, from Amgen Europe B.V, in the therapeutic area of immunology-rheumatology-transplantation / endocrinology-gynaecology-fertility-metabolism / oncology;
- Etravirine, from Janssen-Cilag International N.V., in the therapeutic area of infectious diseases;

Opinion on compliance check

The PDCO adopted a positive opinion on a (full) compliance check for tiotropium bromide (monohydrate), from Boehringer Ingelheim International GmbH, in the therapeutic area of Pneumology-Allergology.

A compliance check is performed to verify that all the measures agreed in a PIP and reflected in the Agency's decision have been conducted in accordance with the decision, including the agreed timelines. Full compliance with all studies/measured contained in the PIP is one of several prerequisites for obtaining the rewards and incentives provided for in Articles 36 to 38 of the Paediatric Regulation.

Before the submission of a request for a compliance check, applicants are encouraged to consult the Agency's Procedural advice for validation of a new marketing authorisation application or extension/variation application and compliance check with an agreed PIP.

Other matters

Inventory of paediatric therapeutic needs: List of products in the therapeutic area of cardiovascular diseases was adopted by the PDCO.

The next meeting of the PDCO will be held on 05-07 September 2012.

– END –

Notes:

1. As of 26 January 2009, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product, or those that submit an application for an extension of indication, a new route of administration, or a new pharmaceutical form of a medicinal product already authorised in the European Union, have to provide either the results of studies in children conducted in accordance with an approved PIP, or an Agency's decision on a waiver or on a deferral.

2. PDCO opinions on PIPs and waivers are transformed into Agency's decisions within the timeframe laid down by the Paediatric Regulation (Regulation (EC) No 1901/2006, as amended). The decisions can be found on the Agency's website at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/pip_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d129

3. More information about the PDCO and the Paediatric Regulation is available in the Regulatory section of the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000023.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800240cd

4. This meeting report, together with other information on the work of the Agency's, can be found on the Agency's website: http://www.ema.europa.eu

Enquiries only to: paediatrics@ema.europa.eu

Annex of the August 2012 PDCO meeting report

	2010 (January to December)	2011 (January to December)	2012 (January to current month)	Cumulative total (2007 to present)
Total number of validated PIP/waiver applications	326	187	122	1266[1]
Applications submitted for a product not yet authorised *(Article 7[2])*	280	153	98	948 *(75%)*
Applications submitted for a product already authorised and still under patent, in view of a submission of a variation/extension for a new indication, pharmaceutical form or route of administration *(Article 8)*	43	33	24	292 *(23%)*
Applications submitted for an off-patent product developed specifically for children with an age-appropriate formulation *(Article 30)*	4	1	0	26 *(2%)*
PIPs and full waiver indications covered by these applications	403	220	148	1732

Number of Paediatric Committee (PDCO) opinions	2010	2011	2012	Cumulative total (2007 to present)
Positive on full waiver	52	45	24	245
Positive on PIP, including potential deferral	201	107	61	574
Negative opinions adopted	7	3	3	30
Positive opinions adopted on modification of a PIP	103	153	110	425
Negative opinions adopted on modification of a PIP	4	2	1	7
Positive opinions on compliance with a PIP	9	9	2	33
Negative opinions on compliance check with a PIP	0	0	0	1
Opinions adopted under Art. 14.2	2	0	0	2

[1] Of which 313 have been requests for a full waiver.
[2] Applications submitted in accordance with the referenced article of Regulation (EC) No 1901/2006, as amended.

Areas covered by PIPs/waiver applications	2010 *(%)*	2011 *(Number of areas covered)**	2012 *(Number of areas covered)**
Neurology	3	11	6
Uro-nephrology	2	4	3
Gastroenterology-hepatology	1	10	4
Pneumology-allergology	41	10	7
Infectious diseases	4	15	18
Cardiovascular diseases	8	21	24
Diagnostics	1	5	2
Endocrinology-gynaecology-fertility-metabolism	6	28	14
Neonatology-paediatric intensive care	0	0	2
Immunology-rheumatology-transplantation	5	13	9
Psychiatry	1	9	0
Pain	1	2	7
Haematology-haemostaseology	4	18	7
Otorhinolaryngology	3	2	1
Oncology	9	19	16
Dermatology	1	10	9
Vaccines	2	12	2
Ophthalmology	4	8	3
Anaesthesiology	2	1	2
Nutrition	0	0	0
Other		7	8

** One PIP can cover several therapeutic areas*